Viktor Adalsteinsson

New Capabilities

Developed MAESTRO technology now powering Oncodetect

Cancer patients often finish treatment not knowing whether it worked. Abbott's new Oncodetect test, launched October 26, tries to answer that question sooner. The blood test tracks up to 5,000 mutations unique to each patient's tumor and can detect cancer DNA at concentrations below one part per million.

Updated Oct 26